最近十几天，先后有3篇重量级的文章被撤稿，一个特点，都是同胞是第一作者，可以想象，发表时的喜悦早被不停地要求重复实验冲刷的一干二净了，最后还是被撤稿。看来搞科研也要如履薄冰才行，要谨慎求证，不要让自己想象的重要性冲昏了头脑。
第一Nature杂志，作者单位加州大学旧金山分校，撤稿原因，文章主要数据不能重复，看到第一作者已经有独立的实验室，如后的日子将是艰难。Nature的撤稿信如下：
Studies identifying APOBEC3G as a post-entry restriction factor for HIV in resting CD4 T cells (Nature 435:108ñ114, 2005).
The authors wish to retract this Letter because they have been unable to reproduce the experiments demonstrating APOBEC3G functions as a post-entry restriction factor in resting CD4 T cells. Two recent studies1, 2 have also challenged this conclusion. However, the authors report that several findings described in this Letter are reproducible, including: (1) low-molecular-mass (LMM) forms of APOBEC3G predominate in resting CD4 T cells and monocytes; (2) LMM APOBEC3G is recruited in high-molecular-mass (HMM) APOBEC3G RNA–protein complexes after activation of T cells or differentiation of monocytes into macrophages; (3) HMM APOBEC3G does not exhibit enzymatic activity; (4) when HMM APOBEC3G is treated with RNase A, LMM APOBEC3G forms are generated and enzymatic activity is restored. and (5) Vif assembles with and polyubiquitylates APOBEC3G present in HMM complexes. Nevertheless, because a central finding of the paper cannot be replicated either internally or externally despite repeated attempts, the authors request that Nature retract the paper and regret any confusion that may have been created by the paper’s publication.
作者的实验室。
第二篇，作者来自康奈尔大学，是做植物研究的，原因是开始对数据的解读有错误，用其他更令人信服的实验无法验证原来的结论。文章发表在PNAS上，已经被引用很多次。 继续阅读 »

最近一篇文章交到了一家杂志审稿人手里，正在等待判决。

今天和一位在西雅图的同道通信，突然想起他的一篇文章的经历，他说他创造了最短稿件被拒绝的记录，时间是2小时。他把一篇文章投到Diabetes杂志，2小时后，主编回信说没有in vivo的数据，拒绝发表，没有审稿，似乎有悖糖尿病杂志的传统，缺乏对科学文章最起码的尊重。

不过这位老兄没有太生气，这样也好，省的浪费时间，比拖你个月再拒绝好多了。

正在整理另一部分（最近1年半）工作，并决定下一步的方向，开始认真研究胰岛alpha细胞分泌胰高血糖素的问题。图为女儿的涂鸦。